Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140218 · ClinicalTrials.gov registry record · Phase 1
R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis
A Phase 1 study, sponsored by Bennett, James P., Jr., M.D., Ph.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00140218: Completed Phase 1 study, sponsored by Bennett, James P., Jr., M.D., Ph.D..
NCT00140218 is a Phase 1 study that has completed, run by Bennett, James P., Jr., M.D., Ph.D.. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00140218, a Phase 1 study, has completed, sponsored by Bennett, James P., Jr., M.D., Ph.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months.
Interventions
- DRUG R(+) pramipexole dihydrochloride monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
What the finished NCT00140218 record still lists
NCT00140218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which R(+) pramipexole dihydrochloride monohydrate is the first listed.
NCT00140218 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00140218 about?
NCT00140218 is a clinical study titled "R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis". The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 mont...
What is the current status of trial NCT00140218?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2005-08. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00140218?
The interventions under investigation include: R(+) pramipexole dihydrochloride monohydrate (DRUG).
Who is sponsoring clinical trial NCT00140218?
This trial is sponsored by Bennett, James P., Jr., M.D., Ph.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00140218's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia